195 related articles for article (PubMed ID: 8647574)
1. [Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].
Byington RP; Jukema JW; Salonen JT; Pitt B; Bruschke AV; Hoen H; Furberg CD; Mancini GB
Fortschr Med; 1996 Mar; 114(8):91-8. PubMed ID: 8647574
[TBL] [Abstract][Full Text] [Related]
2. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.
Byington RP; Jukema JW; Salonen JT; Pitt B; Bruschke AV; Hoen H; Furberg CD; Mancini GB
Circulation; 1995 Nov; 92(9):2419-25. PubMed ID: 7586340
[TBL] [Abstract][Full Text] [Related]
3. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
4. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Yokoyama M; Origasa H;
Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
[TBL] [Abstract][Full Text] [Related]
5. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
Austin PC; Mamdani MM
Circulation; 2005 Aug; 112(9):1296-300. PubMed ID: 16116054
[TBL] [Abstract][Full Text] [Related]
6. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
Boekholdt SM; Agema WR; Peters RJ; Zwinderman AH; van der Wall EE; Reitsma PH; Kastelein JJ; Jukema JW;
Circulation; 2003 May; 107(19):2416-21. PubMed ID: 12742999
[TBL] [Abstract][Full Text] [Related]
7. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
[TBL] [Abstract][Full Text] [Related]
8. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
[TBL] [Abstract][Full Text] [Related]
9. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
10. White blood cell count predicts reduction in coronary heart disease mortality with pravastatin.
Stewart RA; White HD; Kirby AC; Heritier SR; Simes RJ; Nestel PJ; West MJ; Colquhoun DM; Tonkin AM;
Circulation; 2005 Apr; 111(14):1756-62. PubMed ID: 15809366
[TBL] [Abstract][Full Text] [Related]
11. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
13. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
Simes J; Furberg CD; Braunwald E; Davis BR; Ford I; Tonkin A; Shepherd J
Eur Heart J; 2002 Feb; 23(3):207-15. PubMed ID: 11792135
[TBL] [Abstract][Full Text] [Related]
14. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Rouleau J
Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of the West of Scotland Coronary Prevention Study.
Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
[TBL] [Abstract][Full Text] [Related]
16. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
Gresser U; Gathof BS
Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
[TBL] [Abstract][Full Text] [Related]
18. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
19. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
Deedwania PC;
Am Heart J; 2004 Dec; 148(6):1053-9. PubMed ID: 15632893
[TBL] [Abstract][Full Text] [Related]
20. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
Albert MA; Staggers J; Chew P; Ridker PM;
Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
